

## PRESS RELEASE

May 9, 2012

### **SpinalCyte, LLC Reports Results From Animal Studies**

HOUSTON, Texas – **SpinalCyte, LLC**, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts (HDFs), today announced encouraging results from in vivo animal studies completed at Rush University Medical Center under the direction of renowned researcher, Howard An, M.D.

Based on the data analyzed, cell therapy using HDFs, promoted cell differentiation into chondrocytes and proliferation within the disc nucleus over an 8 week period. Furthermore, the therapy resulted in an 80%+ restoration of disc height. “This data suggests a significant improvement over existing therapies and a promising future for development of the SpinalCyte technology”, remarked Dr. An.

“The results exceeded our most optimistic expectations and reveal encouraging cell growth for our next phase of research,” said Pete O’Heeron, Chief Executive Officer.

The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.

#### **About SpinalCyte, LLC**

Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company founded in 2007 for the purpose of developing an innovative and autologous solution for nucleus replacement technology using human dermal fibroblasts. The goal of SpinalCyte is to develop a nucleus regrowth technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

Contact:

Pete O’Heeron, CEO

281.461.6211

[pete@spinalcyte.com](mailto:pete@spinalcyte.com)